Samarth Kulkarni Sells 20,000 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) Stock

CRISPR Therapeutics AG (NASDAQ:CRSPGet Free Report) CEO Samarth Kulkarni sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $72.48, for a total transaction of $1,449,600.00. Following the transaction, the chief executive officer now directly owns 208,122 shares of the company’s stock, valued at $15,084,682.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Samarth Kulkarni also recently made the following trade(s):

  • On Monday, March 11th, Samarth Kulkarni sold 9,802 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $78.26, for a total transaction of $767,104.52.
  • On Tuesday, February 20th, Samarth Kulkarni sold 6,370 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $79.67, for a total transaction of $507,497.90.
  • On Thursday, February 15th, Samarth Kulkarni sold 20,000 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $80.36, for a total transaction of $1,607,200.00.
  • On Monday, January 29th, Samarth Kulkarni sold 50,000 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $60.51, for a total transaction of $3,025,500.00.
  • On Tuesday, January 16th, Samarth Kulkarni sold 20,000 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $62.50, for a total transaction of $1,250,000.00.

CRISPR Therapeutics Stock Up 0.7 %

CRSP stock opened at $71.96 on Wednesday. CRISPR Therapeutics AG has a 52 week low of $37.55 and a 52 week high of $91.10. The company has a fifty day simple moving average of $72.75 and a two-hundred day simple moving average of $60.88. The firm has a market capitalization of $5.78 billion, a P/E ratio of -36.71 and a beta of 1.79.

CRISPR Therapeutics (NASDAQ:CRSPGet Free Report) last released its earnings results on Wednesday, February 21st. The company reported $1.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.95. The firm had revenue of $201.20 million during the quarter, compared to analyst estimates of $148.72 million. CRISPR Therapeutics had a negative net margin of 240.84% and a negative return on equity of 8.09%. The business’s revenue was up 3253.3% on a year-over-year basis. During the same quarter last year, the business earned ($1.41) EPS. As a group, analysts anticipate that CRISPR Therapeutics AG will post -6.28 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Barclays upped their target price on shares of CRISPR Therapeutics from $61.00 to $80.00 and gave the company an “equal weight” rating in a report on Thursday, February 22nd. Mizuho upped their target price on shares of CRISPR Therapeutics from $82.00 to $99.00 and gave the company a “buy” rating in a report on Wednesday, March 6th. Wells Fargo & Company increased their price objective on shares of CRISPR Therapeutics from $55.00 to $70.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 22nd. Truist Financial reissued a “buy” rating on shares of CRISPR Therapeutics in a research note on Friday, December 8th. Finally, TD Cowen cut shares of CRISPR Therapeutics from a “market perform” rating to an “underperform” rating and set a $30.00 price objective for the company. in a research note on Monday, December 11th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $72.94.

Check Out Our Latest Stock Report on CRISPR Therapeutics

Institutional Investors Weigh In On CRISPR Therapeutics

Institutional investors have recently made changes to their positions in the company. Jump Financial LLC increased its stake in CRISPR Therapeutics by 194.7% in the 3rd quarter. Jump Financial LLC now owns 33,307 shares of the company’s stock worth $1,512,000 after buying an additional 22,006 shares during the period. Baker Chad R purchased a new position in CRISPR Therapeutics in the 3rd quarter worth about $2,365,000. Capital Advisors Inc. OK increased its stake in CRISPR Therapeutics by 7.4% in the 3rd quarter. Capital Advisors Inc. OK now owns 231,925 shares of the company’s stock worth $10,527,000 after buying an additional 15,951 shares during the period. Credit Suisse AG increased its stake in CRISPR Therapeutics by 8.8% in the 2nd quarter. Credit Suisse AG now owns 921,656 shares of the company’s stock worth $51,742,000 after buying an additional 74,383 shares during the period. Finally, Invesco Ltd. increased its stake in CRISPR Therapeutics by 1.5% in the 3rd quarter. Invesco Ltd. now owns 136,123 shares of the company’s stock worth $6,179,000 after buying an additional 2,061 shares during the period. Institutional investors own 68.20% of the company’s stock.

CRISPR Therapeutics Company Profile

(Get Free Report)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Further Reading

Insider Buying and Selling by Quarter for CRISPR Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.